PubMed

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.

Diabetes Care. 2009 Jul;32(7):1237-43. Epub 2009 Apr 14.PMID: 19366970 [PubMed - indexed for MEDLINE]Related articlesFree article

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

Diabetes Care. 2009 Jul;32(7):1224-30. Epub 2009 Mar 16.PMID: 19289857 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A.

JAMA. 2000 Apr 5;283(13):1695-702. Erratum in: JAMA 2000 Sep 20;284(11):1384. PMID: 10755495 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

Lewin A, Lipetz R, Wu J, Schwartz S.

Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies.

Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, Pans M.

Diabetes Obes Metab. 2005 Jan;7(1):28-39.PMID: 15642073 [PubMed - indexed for MEDLINE]Related articles

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.

Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC.

Diabetes Care. 1998 Jul;21(7):1154-8.PMID: 9653611 [PubMed - indexed for MEDLINE]Related articlesFree article

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Avilés-Santa L, Sinding J, Raskin P.

Ann Intern Med. 1999 Aug 3;131(3):182-8.PMID: 10428734 [PubMed - indexed for MEDLINE]Related articlesFree article

The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M.

Diabetes Technol Ther. 2007 Aug;9(4):317-26.PMID: 17705687 [PubMed - indexed for MEDLINE]Related articles

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT.

Am J Med. 2004 Feb 15;116(4):223-9.PMID: 14969649 [PubMed - indexed for MEDLINE]Related articles

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group.

Diabetes Care. 2009 Sep;32(9):1649-55. Epub 2009 May 28.PMID: 19478198 [PubMed - indexed for MEDLINE]Related articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1083-91.PMID: 15855571 [PubMed - indexed for MEDLINE]Related articlesFree article

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.

Clin Ther. 2007 Jan;29(1):74-83.PMID: 17379048 [PubMed - indexed for MEDLINE]Related articles